Øyvind Kongstun Arnesen

Øyvind Kongstun Arnesen currently works at VITMED AS, as Chief Executive Officer & Director, Oslo Cancer Cluster NCE, as Chairman, Curida AS, as Director, and Cytovation AS, as Director from 2022.
Mr. Arnesen also formerly worked at Hubro Therapeutics AS, as Chairman & Chief Executive Officer from 2021 to 2024, Ultimovacs ASA, as Chief Executive Officer, Boehringer Ingelheim Norway KS, as Medical Director & Head-Clinical Operations from 2007 to 2012, Bristol-Myers Squibb Norway AS, as Medical Director from 2004 to 2007, and AstraZeneca AS, as Clinical Trial Manager from 1995 to 1996.
Mr. Arnesen received his doctorate degree from the University of Oslo.